enGene Q1 2024 Earnings Report $6.95 -0.02 (-0.29%) As of 04:00 PM Eastern Earnings HistoryForecast enGene EPS ResultsActual EPS$0.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AenGene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AenGene Announcement DetailsQuarterQ1 2024Date3/11/2024TimeN/AConference Call ResourcesPress ReleaseENGN Earnings HistoryPowered by enGene Earnings HeadlinesHead to Head Contrast: enGene (NASDAQ:ENGN) vs. Vaxart (NASDAQ:VXRT)January 20 at 2:15 AM | americanbankingnews.comPorsche Reinvents the Six-Stroke Engine: Check Out The New PatentJanuary 16, 2025 | msn.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.January 22, 2025 | Weiss Ratings (Ad)Fire engines built in West Michigan bound for California wildfiresJanuary 16, 2025 | msn.comLAFD bosses sent just 5 fire engines to Palisades Fire — while holding back 1,000 firefighters and 35 trucks in critical first hoursJanuary 16, 2025 | msn.comHow BMW Perfected The Inline-Six Engine Design Over DecadesJanuary 16, 2025 | msn.comSee More enGene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email. Email Address About enGeneenGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.View enGene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Elevance Health (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)American Express (1/24/2025)HCA Healthcare (1/24/2025)NextEra Energy (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
